Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.